Bempedoic acid/ezetimibe/atorvastatin
Bempedoic acid/ezetimibe/atorvastatin is a combination therapy composed of bempedoic acid, ezetimibe, and atorvastatin. In a randomized study it showed a LDL-C reduction of 63.6 percent, significantly more than bempedoic acid/ezetimibe, and it may also be more effective than bempedoic acid / statin combination therapy.[1][2][3]
References[edit]
- ^ Jadhav, Satyawan B; Crass, Ryan L; Chapel, Sunny; Kerschnitzki, Michael; Sasiela, William J; Emery, Maurice G; Amore, Benny M; Barrett, P Hugh R; Watts, Gerald F; Catapano, Alberico L (3 September 2022). "Pharmacodynamic effect of bempedoic acid and statin combinations: predictions from a dose–response model". European Heart Journal - Cardiovascular Pharmacotherapy. 8 (6): 578–586. doi:10.1093/ehjcvp/pvab064. PMC 9440868.
- ^ Rubino, John; MacDougall, Diane E.; Sterling, Lulu R.; Hanselman, Jeffrey C.; Nicholls, Stephen J. (March 2021). "Combination of bempedoic acid, ezetimibe, and atorvastatin in patients with hypercholesterolemia: A randomized clinical trial". Atherosclerosis. 320: 122–128. doi:10.1016/j.atherosclerosis.2020.12.023. ISSN 1879-1484.
- ^ MacDougall, Diane; Sterling, Lulu Ren; Rubino, John; Hanselman, Jeffrey; Nicholls, Stephen (May 2019). "Efficacy and Safety of Triplet Therapy With Bempedoic Acid, Ezetimibe, and Atorvastatin in Patients with Hypercholesterolemia". Journal of Clinical Lipidology. 13 (3): e55. doi:10.1016/j.jacl.2019.04.091.